Androgen receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Androgen receptor as ChEMBL target CHEMBL3072, mapped to UniProt P15207. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Androgen receptor matters
Androgen receptor is reviewed as Androgen receptor (UniProt P15207); the current evidence base includes 92 approved drugs, 2769 compounds, and 255 assays, with lead potency reaching pChEMBL 10.7.
Androgen receptor Sequence length is 902 aa.
Review this target as Androgen receptor, mapped to UniProt P15207. Sequence length is 902 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 92 approved drugs, 2769 compounds, and 255 assays for this target. The dominant activity type is IC50. CHEMBL3640859 is the current potency anchor at pChEMBL 10.7.
Use CHEMBL3640859 as the tractability anchor when discussing potency (pChEMBL 10.7).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Androgen receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P15207, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL3640859
|
10.7 | IC50 | — |
|
|
No preferred name
CHEMBL3640847
|
10.5 | IC50 | — |
|
|
No preferred name
CHEMBL3640857
|
10.0 | IC50 | — |
|
|
No preferred name
CHEMBL3640853
|
9.7 | IC50 | — |
|
|
No preferred name
CHEMBL3640855
|
9.7 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ENZALUTAMIDE
CHEMBL1082407
|
2012 |
|
|
MIFEPRISTONE
CHEMBL1276308
|
2000 |
|
|
BICALUTAMIDE
CHEMBL409
|
1995 |
|
|
BUDESONIDE
CHEMBL1370
|
1994 |
|
|
DORZOLAMIDE
CHEMBL218490
|
1994 |
|
|
DANAZOL
CHEMBL1479
|
1976 |
|
|
PROGESTERONE
CHEMBL103
|
1976 |
|
|
ESTRADIOL
CHEMBL135
|
1975 |
|
|
HALCINONIDE
CHEMBL1200845
|
1974 |
|
|
METHYLTESTOSTERONE
CHEMBL1395
|
1973 |
|
|
NORETHINDRONE ACETATE
CHEMBL1201146
|
1973 |
|
|
FLUOROMETHOLONE
CHEMBL1200600
|
1972 |
|
|
TESTOSTERONE
CHEMBL386630
|
1972 |
|
|
OXYMETHOLONE
CHEMBL1200585
|
1972 |
|
|
MEGESTROL ACETATE
CHEMBL1201139
|
1971 |
|
|
NORGESTREL
CHEMBL2107797
|
1968 |
|
|
ETHYLESTRENOL
CHEMBL1200623
|
1964 |
|
|
STANOZOLOL
CHEMBL2079587
|
1962 |
|
|
NORETHINDRONE
CHEMBL1162
|
1962 |
|
|
ACETOPHENAZINE
CHEMBL1085
|
1961 |
|
|
SPIRONOLACTONE
CHEMBL1393
|
1960 |
|
|
MEDROXYPROGESTERONE ACETATE
CHEMBL717
|
1959 |
|
|
FLUPHENAZINE
CHEMBL726
|
1959 |
|
|
CHLORMADINONE ACETATE
CHEMBL110691
|
— |